Edwards Lifesciences reported second-quarter revenue of $1.74 billion, up 13.6% year over year, with adjusted earnings of 78 cents per share, a 16.4% increase. TAVR sales reached $1.26 billion, up 10.5% at constant currency, and management raised 2026 TAVR constant-currency growth guidance to 8-9% from 7-9%, while lifting companywide constant-currency sales growth guidance to 10-11% from 9-11%. Transcatheter Mitral and Tricuspid Therapies sales hit $195.9 million, up 44.8% at constant currency, and 2026 TMTT guidance was raised to $760-$780 million from $740-$780 million. The stock trades at a forward 12-month price-to-earnings ratio of 28.78, above the Zacks sub-industry's 27.25 and the S&P 500's 20.66, though near its five-year median of 30. Zacks rates Edwards a Hold with a Growth Score of A, Value Score of D, and Momentum Score of F, suggesting patience rather than treating growth alone as a buy signal.
Edwards Lifesciences CorpStrong Q2 results and raised guidance, but premium valuation noted.
Abbott Laboratories
Boston Scientific Corp